Boehringer Ingelheim looks back proudly on a century of pioneering achievement, first in industrial biotechnology and then in the commercial application of recombinant DNA techniques.
As early as 1895 Boehringer Ingelheim was pioneering large-scale biotech production by using bacteria to produce lactic and citric acid.
For Boehringer Ingelheim the true history of biotechnological production started in 1963 with our research in chicken interferon. This ground-breaking work on interferons led to a number of collaborations that have grown over the years, with Genentech and Bayer Schering among others.
1983 was the year of registration of Berofor (interferon alpha), Boehringer Ingelheim’s first biologic on the market. Our first plant for the fermentation of microorganisms was built in 1985 to produce Berofor and Imukin. That same year a large-scale biotech plant for mammalian cell culture fermentation was built in Biberach, Germany.
Boehringer Ingelheim enters the contract manufacturing business with its first client Schering AG (now part of Bayer Healthcare AG) supplying Betaferon®.
Addition of new large scale facilities in Biberach for mammalian cell culture.
Addition of a new large scale plant in Vienna for microbial fermentation.
Acquisition of US biopharma plant in Fremont, California, located in one of the most important biotech hubs in the world
Launch of Boehringer Ingelheim BioXcellence™, Boehringer Ingelheim's brand for world-class biopharmaceutical contract manufacturing
Boehringer Ingelheim has signed with Zhangjiang Biotech & Pharmaceutical Base Development Company in Pudong, Shanghai a strategic alliance agreement and contract to build a cGMP biopharmaceuticals facility. The new site will provide full range of development and clinical services to Chinese and multi-national customers.
Successful handover of Boehringer Ingelheim’s biopharmaceutical manufacturing site in Shanghai, China. The site is expected to kick off contract manufacturing of biopharmaceuticals on a trial basis under the support of the government.
Boehringer Ingelheim will make a significant investment in a further large scale cell culture biopharmaceutical production facility at its Vienna (Austria) site.